NASDAQ:BIOC - Biocept Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2473 -0.01 (-3.89 %)
(As of 06/21/2018 06:00 AM ET)
Previous Close$0.2473
Today's Range$0.2450 - $0.2745
52-Week Range$0.17 - $1.64
Volume1.06 million shs
Average Volume1.45 million shs
Market Capitalization$17.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Biocept logoBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Debt-to-Equity Ratio0.13
Current Ratio2.41
Quick Ratio2.31

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.07 million
Price / Sales3.33
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book12.37

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-21,610,000.00
Net Margins-561.47%
Return on Equity-445.14%
Return on Assets-196.63%

Miscellaneous

Employees95
Outstanding Shares68,210,000

Biocept (NASDAQ:BIOC) Frequently Asked Questions

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) posted its quarterly earnings data on Tuesday, May, 15th. The medical research company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The medical research company earned $0.81 million during the quarter, compared to analyst estimates of $1.21 million. Biocept had a negative net margin of 561.47% and a negative return on equity of 445.14%. View Biocept's Earnings History.

When is Biocept's next earnings date?

Biocept is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Biocept.

What price target have analysts set for BIOC?

2 brokers have issued 1 year price objectives for Biocept's shares. Their forecasts range from $1.00 to $1.50. On average, they anticipate Biocept's stock price to reach $1.25 in the next year. View Analyst Ratings for Biocept.

Who are some of Biocept's key competitors?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 55)
  • Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations, Sec. & Principal Accounting Officer (Age 60)
  • Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Pavel Tsinberg M.S.E, Associate Director of Technology Devel.

Has Biocept been receiving favorable news coverage?

News headlines about BIOC stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biocept earned a daily sentiment score of 0.22 on Accern's scale. They also gave news coverage about the medical research company an impact score of 45.91 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.2473.

How big of a company is Biocept?

Biocept has a market capitalization of $17.74 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Biocept employs 95 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


MarketBeat Community Rating for Biocept (BIOC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.